Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NINE WOMEN FROM ACROSS THE U.S. SHARE THEIR PERSONAL EXPERIENCES WITH BREAST AUGMENTATION AND RECONSTRUCTION WITHNATRELLE  CELEBRATING CONFIDENCE, SELF-EXPRESSION,AND RESTORATION. IRVINE, CALIF.

ALLERGAN AESTHETICS UNVEILS THE NEW FACES OF NATRELLE AND REAL STORIES OF EMPOWERMENT AND TRANSPARENCY

REPORTS SECOND-QUARTER DILUTED EPS OF $0.52 ON A GAAP BASIS, A DECREASE OF 32.5 PERCENT; ADJUSTED DILUTED EPS OF $2.97, AN INCREASE OF 12.1 PERCENT; THESE RESULTS INCLUDE AN UNFAVORABLE IMPACT OF $0.42 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE DELIVERS SECOND-QUARTER NET REVENUES OF $15.423 BILLION, AN INCREASE OF 6.6 PERCENT ON A REPORTED BASIS OR 6.5 PERCENT ON AN OPERATIONAL BASIS SECOND -QUARTER GLOBAL NET REVENUES FROM THE IMMUNOLOGY PORTFOLIO WERE $7.631 BILLION, AN INCREASE OF 9.5 PERCENT ON A REPORTED BASIS, OR 9.2 PERCENT ON AN OPERATIONAL BASIS; GLOBAL SKYRIZI NET REVENUES WERE $4.423 BILLION; GLOBAL RINVOQ NET REVENUES WERE $2.028 BILLION; GLOBAL HUMIRA NET REVENUES WERE $1.180 BILLION  SECOND -QUARTER GLOBAL NET REVENUES FROM THE NEUROSCIENCE PORTFOLIO WERE $2.683 BILLION, AN INCREASE OF 24.2 PERCENT ON A REPORTED BASIS, OR 24.0 PERCENT ON AN OPERATIONAL BASIS; GLOBAL VRAYLAR NET REVENUES WERE $900 MILLION; GLOBAL BOTOX THERAPEUTIC NET REVENUES WERE $928 MILLION; COMBINED GLOBAL UBRELVY AND QULIPTA NET REVENUES WERE $605 MILLION  SECOND -QUARTER GLOBAL NET REVENUES FROM THE ONCOLOGY PORTFOLIO WERE $1.676 BILLION, AN INCREASE OF 2.6 PERCENT ON A REPORTED BASIS, OR 2.4 PERCENT ON AN OPERATIONAL BASIS; GLOBAL IMBRUVICA NET REVENUES WERE $754 MILLION; GLOBAL VENCLEXTA NET REVENUES WERE $691 MILLION; GLOBAL ELAHERE NET REVENUES WERE $159 MILLION  SECOND -QUARTER GLOBAL NET REVENUES FROM THE AESTHETICS PORTFOLIO WERE $1.279 BILLION, A DECREASE OF 8.1 PERCENT ON A REPORTED BASIS, OR 8.0 PERCENT ON AN OPERATIONAL BASIS; GLOBAL BOTOX COSMETIC NET REVENUES WERE $692 MILLION; GLOBAL JUVEDERM NET REVENUES WERE $260 MILLION RAISES 2025 ADJUSTED DILUTED EPS GUIDANCE RANGE FROM $11.67 - $11.87 TO $11.88 - $12.08, WHICH INCLUDES AN UNFAVORABLE IMPACT OF $0.55 PER SHARE RELATED TO ACQUIRED IPR&D AND MILESTONES EXPENSE INCURRED YEAR-TO-DATE THROUGH THE SECOND QUARTER 2025 NORTH CHICAGO, ILL. , JULY31, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE:ABBV) ANNOUNCED FINA

ABBVIE REPORTS SECOND-QUARTER 2025 FINANCIAL RESULTS

IN STUDY 2 OF THE PIVOTAL PHASE 3 UP-AA CLINICAL PROGRAM, UPADACITINIB (RINVOQ) ACHIEVED THE PRIMARY ENDPOINT, DEMONSTRATING THAT 44.6% AND 54.3% OF PATIENTS WITH SEVERE ALOPECIA AREATA TREATED WITH UPADACITINIB 15 MG AND 30 MG, RESPECTIVELY, REACHED 80% OR MORE SCALP HAIR COVERAGE AT WEEK 24 AS DEFINED BY THE SEVERITY OF ALOPECIA TOOL (SALT) SCORE  201 KEY SECONDARY ENDPOINTS, INCLUDING IMPROVEMENTS IN EYEBROWS AND EYELASHES, AS WELL AS THE PERCENTAGE OF SUBJECTS WITH 90% OR MORE SCALP COVERAGE (SALT  10) AND COMPLETE SCALP HAIR COVERAGE (SALT=0) AT WEEK 24, WERE ALSO MET1 THE SAFETY PROFILE IN ALOPECIA AREATA WAS GENERALLY CONSISTENT WITH THAT IN APPROVED INDICATIONS, AND NO NEW SAFETY SIGNALS WERE IDENTIFIED IN THIS STUDY1 RESULTS FROM THE PARALLEL REPLICATE STUDY (STUDY 1) OF THE PHASE 3 UP-AA CLINICAL PROGRAM ARE ALSO EXPECTED IN THE THIRD QUARTER OF 2025 NORTH CHICAGO, ILL. , JULY 30, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE FIRST OF TWO PIVOTAL STUDIES OF THE PHASE 3 UP-AA CLINICAL PROGRAM EVALUATING THE SAFETY AND EFFICACY OF UPADACITINIB (RINVOQ; 15 MG AND 30 MG, ONCE DAILY) IN ADULT AND ADOLESCENT PATIENTS WITH SEVERE ALOPECIA AREATA (AA) WITH A MEAN BASELINE SALT SCORE OF 83.8 (APPROXIMATELY 16% SCALP HAIR COVERAGE).1 IN STUDY 2, BOTH DOSES OF UPADACITINIB ACHIEVED THE PRIMARY ENDPOINT, WITH 44.6% AND 54.3% OF PATIENTS TREATED WITH UPADACITINIB 15 MG AND 30 MG, RESPECTIVELY, REACHING 80% OR MORE SCALP HAIR COVERAGE (SALT SCORE  20) AT WEEK 24, COMPARED TO 3.4% OF PATIENTS RECEIVING PLACEBO (P

ABBVIE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 UP-AA TRIAL EVALUATING UPADACITINIB (RINVOQ) FOR ALOPECIA AREATA

COMBINATION THERAPY HAS POTENTIAL TO BE AN ALL-ORAL, FIXED-DURATION REGIMEN FOR PREVIOUSLY UNTREATED PATIENTS WITH CLL APPLICATION IS SUPPORTED BY DATA FROM THE PHASE 3 AMPLIFY TRIAL THAT SHOWED STATISTICALLY SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL VS CHEMOIMMUNOTHERAPY REGIMEN OFFERS AN OPPORTUNITY FOR PATIENTS TO TAKE TIME OFF TREATMENT, AN IMPORTANT STEP TOWARD IMPROVED DISEASE MANAGEMENT NORTH CHICAGO, ILL. , JULY 29, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) ANNOUNCED THE SUBMISSION OF A SUPPLEMENTAL NEW DRUG APPLICATION (SNDA) TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR THE FIXED-DURATION, ALL-ORAL COMBINATION REGIMEN OF VENCLEXTA (VENETOCLAX) AND ACALABRUTINIB IN PREVIOUSLY UNTREATED PATIENTS WITH CLL, OFFERING CLL PATIENTS ANOTHER VENCLEXTA COMBINATION REGIMEN WITH THE POTENTIAL FOR TIME-LIMITED TREATMENT.

ABBVIE SUBMITS FOR U.S. FDA APPROVAL OF COMBINATION TREATMENT OF VENCLEXTA (VENETOCLAX) AND ACALABRUTINIB FOR PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

SELECT BUSINESS OWNERS WILL RECEIVE ACCESS TO COACHING, MENTORSHIP, AND COMMUNITY DURING EXCLUSIVE 12-WEEK VIRTUAL "BOOSTCAMP" ADDITIONALLY, 20 ENTREPRENEURS WILL EACH RECEIVE A $20,000 GRANT FROM BOTOX COSMETIC IRVINE, CALIF. , JULY 22, 2025 /PRNEWSWIRE/ -- ALLERGAN AESTHETICS, AN ABBVIE COMPANY (NYSE: ABBV), TODAY ANNOUNCED THE 2025 CLASS OF ENTREPRENEURS WHO WILL PARTICIPATE IN THE CONFIDENCE PROJECT: EMPOWERING WOMEN ENTREPRENEURS.

BOTOX COSMETIC (ONABOTULINUMTOXINA) SELECTS THIS YEAR'S ENTREPRENEURS FOR THE CONFIDENCE PROJECT

ICHNOS GLENMARK INNOVATION (IGI) AND ABBVIE ANNOUNCE EXCLUSIVE GLOBAL LICENSING AGREEMENT FOR ISB 2001, A FIRST-IN-CLASS CD38BCMACD3 TRISPECIFIC ANTIBODY

ICHNOS GLENMARK INNOVATION (IGI) AND ABBVIE ANNOUNCE EXCLUSIVE GLOBAL LICENSING AGREEMENT FOR ISB2001, A FIRST-IN-CLASS CD38BCMACD3 TRISPECIFIC ANTIBODY

ISB 2001 IS CURRENTLY IN PHASE 1 CLINICAL TRIAL IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (R/R MM) NORTH CHICAGO, ILL. AND NEW YORK , JULY10, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) AND IGI THERAPEUTICS SA, A WHOLLY OWNED SUBSIDIARY OF NEW YORK-BASED ICHNOS GLENMARK INNOVATION, INC. (IGI), TODAY ANNOUNCED AN EXCLUSIVE LICENSING AGREEMENT FOR IGI'S LEAD INVESTIGATIONAL ASSET, ISB 2001, DEVELOPED USING IGI'S PROPRIETARY BEAT PROTEIN PLATFORM, FOR ONCOLOGY AND AUTOIMMUNE DISEASES.

ABBVIE AND ICHNOS GLENMARK INNOVATION (IGI) ANNOUNCE EXCLUSIVE GLOBAL LICENSING AGREEMENT FOR ISB 2001, A FIRST-IN-CLASS CD38BCMACD3 TRISPECIFIC ANTIBODY

CAPSTAN'S LEAD ASSET, CPTX2309, IS A TARGETED LIPID NANOPARTICLE (TLNP) THAT DELIVERS AN MRNA ENCODING AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) TO CD8-EXPRESSING CYTOTOXIC T CELLS IN VIVO, AND IS A POTENTIAL FIRST-IN-CLASS PRODUCT FOR TREATING B CELL-MEDIATED AUTOIMMUNE DISEASES PROPOSED ACQUISITION STRENGTHENS ABBVIE'S COMMITMENT TO TRANSFORMING THE FUTURE OF PATIENT CARE WITH CAPSTAN'S INNOVATIVE TLNP PLATFORM TECHNOLOGY NORTH CHICAGO, ILL. AND SAN DIEGO , JUNE 30, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) AND CAPSTAN THERAPEUTICS, INC. ("CAPSTAN"), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO ADVANCINGIN VIVOENGINEERING OF CELLS THROUGH RNA DELIVERY USING TLNPS, TODAY ANNOUNCED A DEFINITIVE AGREEMENT UNDER WHICH ABBVIE WILL ACQUIRE CAPSTAN, INCLUDING CPTX2309, A POTENTIAL FIRST-IN-CLASS IN VIVO TLNP ANTI-CD19 CAR-T THERAPY CANDIDATE, CURRENTLY IN PHASE 1, IN DEVELOPMENT FOR THE TREATMENT OF B CELL-MEDIATED AUTOIMMUNE DISEASES.

ABBVIE TO ACQUIRE CAPSTAN THERAPEUTICS, FURTHER STRENGTHENING COMMITMENT TO TRANSFORMING PATIENT CARE IN IMMUNOLOGY

SKINVIVE BY JUVDERM IS CURRENTLY APPROVED IN THE U.S. AS THE FIRST AND ONLY HYALURONIC ACID MICRODROPLET INJECTABLE INDICATED TO IMPROVE CHEEK SKIN SMOOTHNESS. IF APPROVED, SKINVIVE BY JUVDERM WILL BE THE FIRST HYALURONIC ACID INJECTABLE TREATMENT OPTION AIMING TO REDUCE NECK LINES.

U.S. FOOD AND DRUG ADMINISTRATION ACCEPTS FOR REVIEW ALLERGAN AESTHETICS PREMARKET APPROVAL APPLICATION FOR SKINVIVE BY JUVDERM FOR THE IMPROVEMENT OF NECK APPEARANCE

NORTH CHICAGO, ILL. , JUNE 30, 2025 /PRNEWSWIRE/ --ABBVIE (NYSE: ABBV) WILL ANNOUNCE ITS SECOND-QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, JULY 31, 2025, BEFORE THE MARKET OPENS.

ABBVIE TO HOST SECOND-QUARTER 2025 EARNINGS CONFERENCE CALL

THE GLOBAL ELAHERE MARKET IS SET FOR RAPID GROWTH, PROJECTED TO SURGE TO $6.07 BILLION BY 2034 AT A CAGR OF 28.68%. KEY GROWTH DRIVERS INCLUDE RISING OVARIAN CANCER PREVALENCE, HEALTHCARE ACCESS IN EMERGING MARKETS, AND INCREASED DEMAND FOR PERSONALIZED MEDICINE. DESPITE CHALLENGES LIKE HIGH COSTS AND COMPETITION, THE MARKET, LED BY ABBVIE INC. (IMMUNOGEN), PRESENTS VAST OPPORTUNITIES, PARTICULARLY IN ONLINE PHARMACIES AND HOSPITAL SEGMENTS. THE FASTEST GROWTH WILL OCCUR IN WESTERN AND EASTERN EUROPE. STRATEGIC COLLABORATIONS AND TARGETED THERAPIES ARE RECOMMENDED FOR MAXIMIZING MARKET POTENTIAL. THE GLOBAL ELAHERE MARKET IS SET FOR RAPID GROWTH, PROJECTED TO SURGE TO $6.07 BILLION BY 2034 AT A CAGR OF 28.68%. KEY GROWTH DRIVERS INCLUDE RISING OVARIAN CANCER PREVALENCE, HEALTHCARE ACCESS IN EMERGING MARKETS, AND INCREASED DEMAND FOR PERSONALIZED MEDICINE. DESPITE CHALLENGES LIKE HIGH COSTS AND COMPETITION, THE MARKET, LED BY ABBVIE INC. (IMMUNOGEN), PRESENTS VAST OPPORTUNITIES, PARTICULARLY IN ONLINE PHARMACIES AND HOSPITAL SEGMENTS. THE FASTEST GROWTH WILL OCCUR IN WESTERN AND EASTERN EUROPE. STRATEGIC COLLABORATIONS AND TARGETED THERAPIES ARE RECOMMENDED FOR MAXIMIZING MARKET POTENTIAL.

ELAHERE MARKET OPPORTUNITIES AND STRATEGIES TO 2034: ABBVIE SECURES EUROPEAN APPROVAL FOR ELAHERE IN PLATINUM-RESISTANT OVARIAN CANCER

NORTH CHICAGO, ILL. , JUNE 20, 2025 /PRNEWSWIRE/ -- THE BOARD OF DIRECTORS OFABBVIE INC. (NYSE: ABBV) TODAY DECLARED A QUARTERLY CASH DIVIDEND OF $1.64 PER SHARE.

ABBVIE DECLARES QUARTERLY DIVIDEND

TEMPLE, A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, HEAD-TO-HEAD STUDY, EVALUATED THE TOLERABILITY, SAFETY AND EFFICACY OF ATOGEPANT COMPARED TO TOPIRAMATE FOR THE PREVENTIVE TREATMENT OF MIGRAINE IN ADULT PATIENTS WITH A HISTORY OF FOUR OR MORE MIGRAINE DAYS PER MONTH 1 ATOGEPANT MET THE PRIMARY ENDPOINT OF FEWER TREATMENT DISCONTINUATIONS ATTRIBUTED TO ADVERSE EVENTS VERSUS TOPIRAMATE, AND ALL SIX SECONDARY ENDPOINTS ACHIEVED STATISTICAL SIGNIFICANCE FOR SUPERIORITY VERSUS TOPIRAMATE, DEMONSTRATING CLINICAL EFFICACY 1 FULL RESULTS FROM THE TEMPLE STUDY WILL BE PRESENTED AT AN UPCOMING MEDICAL MEETING NORTH CHICAGO, ILL. , JUNE 18, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM ITS PHASE 3 TEMPLE MULTICENTER, RANDOMIZED, DOUBLE-BLIND, HEAD-TO-HEAD STUDY EVALUATING THE TOLERABILITY, SAFETY AND EFFICACY OF ATOGEPANT (QULIPTA /AQUIPTA, 60 MG ONCE DAILY) COMPARED TO THE HIGHEST TOLERATED DOSE OF TOPIRAMATE (50, 75 OR 100 MG/DAY) IN ADULT PATIENTS WITH A HISTORY OF FOUR OR MORE MIGRAINE DAYS PER MONTH.1 THE STUDY MET THE PRIMARY ENDPOINT OF TREATMENT DISCONTINUATION DUE TO ADVERSE EVENTS (AES), DEMONSTRATING THAT ATOGEPANT, A CALCITONIN GENE-RELATED PEPTIDE (CGRP) RECEPTOR ANTAGONIST, HAD FEWER DISCONTINUATIONS DUE TO AES THAN TOPIRAMATE, AN ANTICONVULSANT MEDICATION ALSO APPROVED FOR MIGRAINE PREVENTION.

ABBVIE ANNOUNCES NEW DATA DEMONSTRATING ATOGEPANT (QULIPTA / AQUIPTA) ACHIEVES SUPERIORITY ACROSS ALL ENDPOINTS IN PHASE 3 HEAD-TO-HEAD STUDY COMPARED TO TOPIRAMATE FOR MIGRAINE PREVENTION

NORTH CHICAGO, ILL. , JUNE 16, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) ANNOUNCED THE GLOBAL PHASE 3 VERONA TRIAL EVALUATING VENETOCLAX IN COMBINATION WITH AZACITIDINE IN THE TREATMENT OF NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROME (HR-MDS) DID NOT MEET THE PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS) WITH A HAZARD RATIO (HR) OF 0.908; STRATIFIED LOG-RANK, P=0.3772.

ABBVIE PROVIDES UPDATE ON VERONA TRIAL FOR NEWLY DIAGNOSED HIGHER-RISK MYELODYSPLASTIC SYNDROMES

THE FDA HAS APPROVED ABBVIE'S RINVOQ (UPADACITINIB) FOR THE TREATMENT OF GIANT CELL ARTERITIS, MAKING IT THE NINTH APPROVED INDICATION FOR THE DRUG. THIS ALSO MARKS THE FIRST TIME AN ORAL JAK INHIBITOR HAS BEEN APPROVED FOR THIS PREVALENT FORM OF VASCULITIS IN WESTERN COUNTRIES. RINVOQ'S APPROVAL HAS SPARKED COMPETITION AMONG OTHER PHARMACEUTICAL COMPANIES IN THE GIANT CELL ARTERITIS MARKET. THE FDA HAS APPROVED ABBVIE'S RINVOQ (UPADACITINIB) FOR THE TREATMENT OF GIANT CELL ARTERITIS, MAKING IT THE NINTH APPROVED INDICATION FOR THE DRUG. THIS ALSO MARKS THE FIRST TIME AN ORAL JAK INHIBITOR HAS BEEN APPROVED FOR THIS PREVALENT FORM OF VASCULITIS IN WESTERN COUNTRIES. RINVOQ'S APPROVAL HAS SPARKED COMPETITION AMONG OTHER PHARMACEUTICAL COMPANIES IN THE GIANT CELL ARTERITIS MARKET.

GIANT-CELL ARTERITIS MARKET HEATS UP WITH ABBVIE'S RINVOQ APPROVAL | DELVEINSIGHT

WATERTOWN, MASS.--(BUSINESS WIRE)--ENANTA PHARMACEUTICALS, INC. (NASDAQ:ENTA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEDICATED TO CREATING SMALL MOLECULE DRUGS FOR VIRAL INFECTIONS AND IMMUNOLOGICAL DISEASES, TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) HAS APPROVED A LABEL EXPANSION FOR MAVYRET (GLECAPREVIR/PIBRENTASVIR), AN ORAL PANGENOTYPIC DIRECT ACTING ANTIVIRAL (DAA) THERAPY. IT IS NOW APPROVED AS THE ONLY EIGHT-WEEK TREATMENT FOR ADULTS AND PEDIATRIC PATIENTS THREE.

ENANTA PHARMACEUTICALS' PARTNER ABBVIE RECEIVES U.S. FDA APPROVAL OF AN EXPANDED INDICATION FOR MAVYRET (GLECAPREVIR/PIBRENTASVIR) AS THE FIRST AND ONLY TREATMENT FOR PEOPLE WITH ACUTE HEPATITIS C VIRUS

MAVYRET (GLECAPREVIR/PIBRENTASVIR) IS THE FIRST AND ONLY ORAL EIGHT-WEEK PANGENOTYPIC TREATMENT OPTION APPROVED FOR PEOPLE WITH ACUTE OR CHRONIC HEPATITIS C VIRUS (HCV)* WITH THIS APPROVAL, PROVIDERS CAN NOW TREAT HCV PATIENTS IMMEDIATELY AT THE TIME OF DIAGNOSIS HCV IS A CURABLE CONDITION, BUT PATIENTS CAN OFTEN GO UNDIAGNOSED.1 IF LEFT UNTREATED, PEOPLE WITH ACUTE HCV COULD PROGRESS TO CHRONIC DISEASE, INCLUDING LIVER-RELATED COMPLICATIONS, SUCH AS CIRRHOSIS OR LIVER CANCER1 THE APPROVAL SUPPORTS GLOBAL CLINICAL GUIDELINES TO ADVANCE TESTING AND TREATMENT FOR PEOPLE WITH HCV REGARDLESS OF CHRONICITY, AND SUPPORTS PUBLIC HEALTH GOALS FOR DISEASE ELIMINATION NORTH CHICAGO, ILL. , JUNE 11, 2025 /PRNEWSWIRE/ -- ABBVIE (NYSE: ABBV) TODAY ANNOUNCED THAT THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVED A LABEL EXPANSION FOR MAVYRET (GLECAPREVIR/PIBRENTASVIR), AN ORAL PANGENOTYPIC DIRECT ACTING ANTIVIRAL (DAA) THERAPY.

U.S. FDA APPROVES EXPANDED INDICATION FOR ABBVIE'S MAVYRET (GLECAPREVIR/PIBRENTASVIR) AS FIRST AND ONLY TREATMENT FOR PEOPLE WITH ACUTE HEPATITIS C VIRUS

AbbVie Inc.

ABBV

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AbbVie Inc.

ABBV.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

ABBV